Abstract
To the Editor: Kielstein et al1 describe the effects of the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA), in humans in vivo but do not make reference to two previous human studies.2,3 In the original paper describing the presence of ADMA in human plasma and its accumulation in chronic renal failure, Vallance et al2 also described the effects of ADMA in isolated blood vessels, on blood pressure in the guinea pig, and on forearm blood flow in healthy human subjects. They described an 8.3% fall in forearm blood flow after an 8 μmol/min ADMA infusion.2 It was this finding that led …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
